skip to Main Content

Abemaciclib is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition

Abemaciclib is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition
Mutation or promoter hypermethylation of CDKN2A is found in over 90% of pancreatic ductal adenocarcinomas (PDAC) and leads to loss of function of cell cycle inhibitors p16 (INK4A) and p14 (ARF) resulting in unchecked proliferation. The CDK4/6 inhibitor, abemaciclib (Lilly, IN) has nanomolar IC50’s in PDAC cell lines and decreases growth through inhibition of phospho-Rb (pRb), G1 cell cycle arrest, apoptosis, and the senescent phenotype detected with β-galactosidase staining and relevant mRNA elevations.

Read more . . . 


Back To Top